SCHEMBL7077840

SCHEMBL7077840

O=C(O)C[C@@H](CS(=O)(=O)c1ccc(F)cc1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABBR2 O75899 1/20 0.49
GABBR1 Q9UBS5 1/20 0.49
FNTA P49354 1/20 0.48
FNTB P49356 1/20 0.48
HSD11B1 P28845 4/20 0.47
EEF2K O00418 2/20 0.46
MAPT P10636 1/20 0.41
MMP2 P08253 2/20 0.41
MMP14 P50281 2/20 0.41
KEAP1 Q14145 2/20 0.41
NFE2L2 Q16236 2/20 0.41
MMP1 P03956 1/20 0.41
MMP3 P08254 1/20 0.41
MMP9 P14780 1/20 0.41
MMP12 P39900 1/20 0.41
MMP13 P45452 1/20 0.41
MMP7 P09237 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077860 1.00 GABBR2 (0.49) GABBR2GABBR1FNTAFNTBHSD11B1
SCHEMBL8909238 0.89 GABBR2 (0.56) GABBR2GABBR1HSD11B1EEF2KMAPT
SCHEMBL7073753 0.87 GABBR2 (0.50) GABBR2GABBR1HSD11B1EEF2KMAPT
Ephedrine SCHEMBL7073757 0.86 KMT2A (0.52) GABBR2GABBR1FNTAFNTBHSD11B1
SCHEMBL7079059 0.85 ALDH1A1 (0.45) FNTAFNTBHSD11B1EEF2KMAPT
SCHEMBL7080823 0.82 GABBR2 (0.49) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL5278801 0.80 BDKRB1 (0.47) GABBR2GABBR1FNTAFNTBMAPT
SCHEMBL7133113 0.80 MEN1 (0.47) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL27603418 0.80 HSD11B1 (0.51) GABBR2GABBR1HSD11B1MAPTMMP2
SCHEMBL6772429 0.78 KMT2A (0.47) FNTAFNTBHSD11B1KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003059872-A1 AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS BAYER PHARMACEUTICALS CORPORATION (US) 2003-07-24 WO disclosed